A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults

Healthy Clinical Trial

Official title:

A Single Center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Trial for Safety and Preliminary Immunogenicity of a Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults, on Day 0 and 21 Intramuscularly

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01676675
• Other study ID #: JSVCT011
• Status: Withdrawn
• Phase: Phase 1
• First received: August 29, 2012
• Last updated: March 14, 2013
• Start date: August 2012
• Est. completion date: March 2013

Study information

• Verified date: March 2013
• Source: Jiangsu Province Centers for Disease Control and Prevention
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Influenza is an acute respiratory infection caused by influenza virus with high incidence and serious complications even causing death. According to the announcement released by the World Health Organization (WHO), the number of global annual influenza case was 0.6 to 1.2 billion and 0.5 to 1 million people died. The emergence of a new subtype of influenza virus may cause an influenza pandemic with occurence once every 10 to 50 years which cause serious adverse consequences for human health and social welfare worldwide.

From 1997 to 2003，the H5N1 virus infection has increased highly and gradually spreaded to Europe, Africa and other countries and regions. High mortality caused by H5N1 virus has attracted the WHO and national government great attention. So it is meaningful to develop vaccine to provide effective antibody to reduce the number of infections.

The objective of this study is to evaluate the safety and preliminary immunogenicity of a whole virus inactivated influenza H5N1 vaccine.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years to 60 Years

Eligibility

Inclusion Criteria:

• Healthy subjects aged from 12 to 60 years old of normal intelligence;

• The subjects' guardians are able to understand and sign the informed consent;

• Subjects established as healthy after medical history questioning, physical examination and clinical decision;

• Subjects who can comply with the requirements of the clinical trial protocol;

• Subjects who have never received influenza H5N1 vaccine and other preventive products;

• Subjects with temperature =37°C on axillary setting.

Exclusion Criteria:

Exclusion Criteria for the first dose:

• Women in pregnancy / lactation or plan to be pregnant during the study;

• The subject has a history of allergy or is allergic with any Ingredient of vaccine, such as egg, ovalbumin;

• Had serious adverse reactions in previous vaccination, such as allergies, hives, difficult breath, angioneurotic edema or abdominal pain;

• Autoimmune diseases or immune deficiency;

• Had asthma, over the past two years, the condition is unstable in need of emergency treatment, hospitalization and oral or intravenous corticosteroids;

• Diabete (type I or type II) not including gestational diabete;

• Thyroidectomy history, or treatment because of thyroid diseases in the past 12 months;

• Over the past 3 years, severe angioneurotic edema, or need treatment in the past 2 years;

• Severe hypertension and blood pressure is still more than 150/100 mmHg after drug maintenance therapy;

• coagulation abnormalities diagnosed by doctor (such as lack of coagulation factors, coagulation disorder diseases, platelet abnormality) or coagulation disorder;

• Malignancy, active or treated tumor without explicitly been cured, or the possibility of a recurrence during the study period;

• Epilepsy not including alcohol epilepsy of stop drinking in the first 3 years or the simplicity not requiring treatment in the past 3 years;

• Asplenia, functional asplenia, and any circumstances leading to asplenia or splenectomy;

• Guillain-Barre syndrome;

• Had immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray to treat allergic rhinitis and corticosteroid treatment of the acute uncomplicated dermatitis) within the past six months;

• Received immune globulin in three months before study;

• Received other experimental drugs in 30 days before study;

• Received live attenuated vaccine in 30 days before study;

• Receiving subunit or inactivated vaccines in 14days before study, such as pneumococcal vaccine or allergy treatment;

• In prevention or treatment of the anti-TB (antituberculosis) now;

• Had fever (axillary temperature = 38.0?) 3 days before vaccination or had any acute illness in the past five days requiring systemic antibiotics or antiviral therapy);

• The subject is unable to comply with the study requirements because of psychology, or had mental illness or dual-stage affective psychosis not well controlled within the past two years or had psychology in medication and suicidal tendency in the past five years;

• According to the researcher, contrary to the study protocol or effect signed informed consent due to a variety of medical, psychological, social conditions, occupational factors or other conditions.

Exclusion Criteria for the second dose:

• Had any vaccination-related Grade 3 or more adverse reactions in 72 hours after first vaccination;

• Any situation meets the exclusion criteria stated in the exclusion criteria for first dose;

• Had serious adverse reactions caused by the study vaccination.

• Acute infection;

• Any condition the investigator believed may affect the evaluation of the vaccine.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Healthy

Intervention

Biological:
• 7.5µg /0.5ml
whole virus inactivated influenza H5N1 vaccine of 7.5µg /0.5ml, two doses, 21 days interval
• 15.0µg /0.5ml
whole virus inactivated influenza H5N1 vaccine of 15.0µg /0.5ml, two doses, 21 days interval
• 30.0µg /0.5ml
whole virus inactivated influenza H5N1 vaccine of 30.0µg /0.5ml, two doses, 21 days interval
• 0/0.5ml placebo
0/0.5ml placebo, two doses, 21 days interval

Locations

Country	Name	City	State
China	Jiangsu Provincial Center for Diseases Control and Prevention	Nanjing	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Jiangsu Province Centers for Disease Control and Prevention	Wuhan Institute of Biological Products Co.,Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the safety of whole virus inactivated influenza H5N1 vaccine in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	Frequency of systemic and local adverse reactions within 21 days after the first doses of whole virus inactivated influenza H5N1 vaccine in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	21 days after the first dose	Yes
Primary	the safety of whole virus inactivated influenza H5N1 vaccine in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	Frequency of systemic and local adverse reactions within 21 days after the second doses of whole virus inactivated influenza H5N1 vaccine in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	21 days after the second dose	Yes
Primary	the immunogenicity of the vaccine after first dose	the seroconversion rate and GMFI of antibodies on day 21 after first dose with different formulation vaccines in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	on day 21±3 days	No
Primary	the immunogenicity of the vaccine after second dose	the seroconversion rate and GMFI of antibodies on day 21 after second dose with different formulation vaccines in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	on day 42±7 days	No
Primary	the immunogenicity of the vaccine after whole immunization	the seroconversion rate and GMFI of antibodies 3 months after the second dose with different formulation vaccines in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	3 months after second dose (±14 days)	No
Secondary	abnormal change of hematological examination and the function of liver and kidney after first dose	abnormal change of hematological examination and the function of liver and kidney 3 days after first dose with different formulation vaccines in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	3 days after first dose	Yes
Secondary	abnormal change of hematological examination and the function of liver and kidney after second dose	abnormal change of hematological examination and the function of liver and kidney 3 days after second dose with different formulation vaccines in healthy adolescents aged from 12-17 years and adults aged from 18-60 years	3 days after second dose	Yes